Multiple RNA splicing and the presence of cryptic RNA splice donor and acceptor sites may contribute to low expression levels and poor immunogenicity of potential DNA vaccines containing the env gene of equine infectious anemia virus (EIAV)

Veterinary Microbiology

Volumn 88, Issue 2, 2002, Pages 127-151

  Zhou, W ^a   Cook, R F ^a   Cook, S J ^a   Ghabrial, N N ^a   Berger, S L ^a   Issel, C J ^a   Hammond, S A ^b   Montelaro, R C ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cryptic RNA splice sites; DNA vaccination; Equine infectious anemia virus; Multiple RNA splicing

Indexed keywords

DNA VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS RNA; VIRUS VACCINE; GLYCOPROTEIN; GLYCOPROTEIN GP 90; POLYPEPTIDE; RNA; TRANSFER RNA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CHEMISTRY; ENVELOPE GENE; EQUINE INFECTIOUS ANEMIA VIRUS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HORSE; HORSE DISEASE; IMMUNOLOGY; METHODOLOGY; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; MUTATION; NUCLEOTIDE SEQUENCE; RNA SPLICING; SITE DIRECTED MUTAGENESIS; STOP CODON; ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANTIGENICITY; CELL STRAIN COS1; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MOLECULAR WEIGHT; NONHUMAN; PLASMID; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; CLONING, MOLECULAR; CODON, TERMINATOR; EQUINE INFECTIOUS ANEMIA; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, ENV; GENES, ENV; HORSES; INFECTIOUS ANEMIA VIRUS, EQUINE; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; RNA SPLICING; RNA, VIRAL; TRANSFECTION; VACCINES, DNA; VIRAL VACCINES; ANIMAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; MAMMALIA; VECTORS;

EID: 0037173912     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1135(02)00099-8     Document Type: Article

References (69)

1. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage
2. EIAV genomic organization: Further characterization by sequencing of purified glycoproteins and cDNA
3. Lentivirus antigen purification and characterization: Isolation of equine infectious anemia virus gag and env proteins in one step by reverse phase HPLC and application to human immunodeficiency virus glycoproteins
4. Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies
5. Biological features of genetic immunization (review)
6. Analysis of multiple mRNAs from pathogenic equine infectious anemia virus (EIAV) in an acutely infected horse reveals a novel protein, Ttm, derived from the carboxy terminus of the EIAV transmembrane protein
7. Biological characterization of Rev variation in equine infectious anemia virus
8. Binding of equine infectious anemia virus Rev to an exon splicing enhancer mediates alternative splicing and nuclear export of viral mRNAs
9. Developmental regulation of RNA transcript destabilization by A+U-rich elements is AUF1-dependent
10. Immune responses in mice, cattle and horses to a DNA vaccine for vesicular stomatitis
11. Regulation by HIV Rev depends upon recognition of splice sites
12. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells
13. Equine infectious anemia virus: Immunopathogenesis and persistence
14. Interplay of two functionally and structurally distinct domains of the c-fos AU-rich element specifies its mRNA-destabilizing function
15. Equine infectious anemia
16. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus
17. Responses of ponies to challenge with equine infectious anemia virus following exposure to recombinant gp90 or viral p26 immunogens
18. Regulation of human immunodeficiency virus replication (review)
19. Lentivirus envelope sequences and proviral genomes are stabilized in Escherichia coli when cloned in low-copy-number plasmid vectors
20. DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice
21. DNA vaccines: Vector design, delivery and antigen presentation
22. Identification of the activation domain of equine infectious anemia virus rev
23. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens
24. Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies
25. Codon usage limitation in the expression of HIV-1 envelope glycoprotein
26. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process
27. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus
28. Hybridization probe size control: Optimized oligolabelling
29. Antigenic analysis of equine infectious anemia virus (EIAV) variants by using monoclonal antibodies: Epitopes of glycoprotein gp90 of EIAV stimulate neutralizing antibodies
30. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus
31. Possible involvement of proteasomes (prosomes) in AUUUA-mediated mRNA decay
32. CpG motifs as immune adjuvants
33. Antigenic drift of equine infectious anemia virus in chronically infected horses
34. Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs
35. Immune responses to DNA vaccines (review)
36. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
37. AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: The functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A)
38. DNA vaccines: A review
39. Unraveling a cytoplasmic role for hnRNP D in the in vivo mRNA destabilization directed by the AU-rich element
40. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene
41. Equine infectious anemia virus trans-regulatory protein Rev controls viral mRNA stability, accumulation, and alternative splicing
42. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins
43. Frequency of memory cytotoxic T lymphocytes to equine infectious anemia virus proteins in blood from carrier horses
44. Equine retroviruses
45. The Tat protein of equine infectious anemia virus is encoded by at least three types of transcripts
46. Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus
47. Equine infectious anemia virus, a putative lentivirus, contains polypeptides analogous to prototype-C oncornaviruses
48. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection
49. Structural and functional characterization of rev-like transcripts of equine infectious anemia virus
50. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection
51. The open reading frame ORF S3 of equine infectious anemia virus is expressed during the viral life cycle
52. Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1
53. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation
54. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression
55. The immunopathogenesis of equine infectious anemia virus
56. Development and use of an equine infectious anemia donkey leucocyte attenuated vaccine
57. The c-fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways
58. Cloning and characterization of cDNAs encoding equine infectious anemia virus tat and putative Rev proteins
59. Quantitative measurement of equine cytokine mRNA expression by polymerase chain reaction using target-specific standard curves
60. The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function
61. Identification of an RNA sequence within an intracisternal-A particle element able to replace Rev-mediated posttranscriptional regulation of human immunodeficiency virus type 1
62. Corticosteroid immunosuppression and monoclonal antibody-mediated CD5+ T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses
63. Heterologous protection against influenza by injection of DNA encoding a viral protein
64. Enhancement of DNA vaccine potency using conventional aluminum adjuvants
65. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons
66. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein
67. Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate
68. Modulation of the fate of cytoplasmic mRNA by AU-rich elements: Key sequence features controlling mRNA deadenylation and decay
69. Continuous propagation of RRE(-) and Rev(-)RRE(-) human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes